Katy K. Tsai

MD

Oncologist and melanoma specialist

Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.

In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy.

Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow.

Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.

  • Education

    Brown University School of Medicine, 2010

  • Residencies

    University of North Carolina School of Medicine, Internal Medicine, 2013

  • Fellowships

    UCSF, Medical Oncology, 2015

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Assistant Professor

Clinics I work with

Melanoma & Skin Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

My reviews

4.9

Overall Experience
183 Reviews
we were VERY impressed with Dr. Tsai and her listening to and responding to our questions as well as establishing a plan to get answers to determine the extent of my cancer
Explained things in a way that was easy to understand
182 Reviews
Did the doctor pay attention to your concerns
182 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
178 Reviews
Knew the important information about your medical history
181 Reviews
The provider showed respect for what you had to say
181 Reviews
The provider spent enough time with me
181 Reviews
Decorative Caduceus

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Percentage of subjects with adverse events (AEs)

Recruiting

Decorative Caduceus

A Phase 1B Study of RP1 in Transplant Patients With Advanced Cutaneous Squamous Cell Carcinoma

Recruiting

Decorative Caduceus

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

RFS is defined as time from registration to recurrence of disease or death from any cause.

Recruiting

Decorative Caduceus

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...

Recruiting

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.

Share